Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

biotech.guru 2 posts  |  Last Activity: Feb 1, 2015 3:38 PM Member since: Feb 9, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    I can imagine 3 simultaneous phase 3s How to pay?

    by jacosa Jan 30, 2015 10:22 AM
    biotech.guru biotech.guru Feb 1, 2015 3:38 PM Flag

    True for cash burning company which I think incy has turned the corner since they now have working capital. Your reasoning is right if they did not generate sales. Check their statement of cash flow very revealing. I would be interested to see what the 10k financials will look like.

  • Reply to

    I can imagine 3 simultaneous phase 3s How to pay?

    by jacosa Jan 30, 2015 10:22 AM
    biotech.guru biotech.guru Jan 31, 2015 6:45 PM Flag

    Jacosa, I think you have great science but again your financial analysis are always flawed. Last quarter incy reported $530M in cash and marketable securities. The cash has been growing at a rate of $50 to $100m annualy. The company has been some what cash neutral from operation, growing sales have covered r&d expenditures and additional milestones received like the $60m or the just announced $25m are paying for the other sg&a expenditures. Most interestingly they have added cash with stock options. This being said if a p3 cost is $100m it is not all spent in one year but rather over maybe 24, 36 or 48 months. One can also expect that certain P3 will wind down while others start so the impact of one study is not necessarily cumulative. Assuming that Jakafi generates $80 to $100m a quarter with an additional growth coming from the newly approved PV and that p3 costs are not all starting at the same time and costs are spread over 2 to 3 years, Incy seems to have well enough cash resources to pay for 3 to 4 p3 programs.

INCY
94.36+5.16(+5.78%)Mar 27 4:00 PMEDT